Eloxx Pharmaceuticals, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 31, 2023. This is an annual report, not a standalone fourth-quarter report. Eloxx is a clinical-stage biopharmaceutical company with no approved products and no product revenue.
Business context and pipeline
The company develops ribosome-modulating drug candidates for rare genetic diseases. Its main clinical program is ELX-02, now being studied subcutaneously in a small Phase 2 Alport syndrome trial. ZKN-013 is in preclinical development for RDEB/JEB and familial adenomatous polyposis (FAP); Eloxx submitted an IND for RDEB on March 24, 2023. The company also completed IND-enabling studies for inhaled ELX-02 in cystic fibrosis (CF).
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $23.7 million | $22.9 million |
| General and administrative expense | $10.7 million | $20.4 million |
| Total operating expenses | $34.4 million | $66.0 million |
| Operating loss | $34.4 million | $66.0 million |
| Other expense, net | $1.6 million | $0.7 million |
| Net loss | $36.1 million | $66.7 million |
| Net cash used in operations | $31.8 million | $35.0 million |
Operating margins are not meaningful because the company had no product revenue. The smaller 2022 net loss mainly reflects the absence of the $22.7 million acquired in-process R&D charge recorded in 2021 for the Zikani acquisition and lower G&A, including reduced stock-based compensation; R&D expense increased modestly.
Cash and cash equivalents were $19.2 million at year-end, down from $42.3 million; cash, cash equivalents and restricted cash totaled $19.5 million. Financing activities provided $8.8 million in 2022, principally collaboration-partner advances. Accumulated deficit was $274.4 million. Total assets were $21.1 million, total liabilities $31.8 million, and stockholders’ deficit $10.7 million. Current assets of $20.1 million were below current liabilities of $23.1 million.
At December 31, 2022, Hercules term-loan principal outstanding was $12.5 million; the balance-sheet carrying value was $11.7 million, including debt discount and related presentation items. In March 2023, Eloxx repaid $7.5 million, leaving $5.0 million principal; principal payments were deferred to September 2023, with maturity in April 2025. The cash covenant was reduced to $2.25 million, potentially falling to zero if specified equity funding is raised.
Material changes, outlook and risks
- CF setback: The Phase 2 trial of subcutaneous ELX-02 plus ivacaftor did not meet secondary efficacy endpoints for sweat chloride or lung function. Eloxx ended subcutaneous CF development in September 2022. The Cystic Fibrosis Foundation stopped further funding, leaving $7.4 million of the amended award unavailable. Inhaled CF development depends on future CFF funding.
- Alport program: The Phase 2 trial began in November 2022, targets up to eight patients, and evaluates safety and proteinuria after two months of dosing. First patients were dosed in February 2023; topline results were expected in the first half of 2023. The filing provides no guarantee of efficacy or funding for subsequent trials.
- Going concern: Management said year-end cash was insufficient for at least the next 12 months after filing, and the auditor identified substantial doubt about the company’s ability to continue as a going concern. Additional financing is necessary and not assured; possible responses include reducing or deferring expenses, delaying or terminating programs, or partnering/licensing assets.
- Financing and debt: The $7.5 million Hercules tranche was unavailable after the company failed to meet its milestone requirements. A further $10.0 million tranche was subject to lender investment-committee discretion. The March 2023 repayment and covenant amendment are subsequent events, not year-end cash or debt figures.
- Other material items: Eloxx effected a 1-for-40 reverse stock split in December 2022. It regained Nasdaq’s minimum bid-price compliance but still faced a separate minimum market-value compliance deadline of April 10, 2023. It reported no material pending legal proceedings and no off-balance-sheet arrangements.
- Execution risks: Development depends on clinical results, patient recruitment, regulatory approval, third-party manufacturers and CROs, intellectual-property protection, and access to capital. ELX-02 also showed renal toxicity in preclinical animals at doses above those expected for clinical use; the company notes the potential for adverse events.
Key facts for investors to verify
- Updated cash runway, financing completed or available, and the effects of the March 2023 Hercules repayment on liquidity and covenant compliance.
- Final Alport Phase 2 enrollment, safety and efficacy results, and any decision or funding to advance the program.
- Whether the ZKN-013 RDEB IND became effective and the timing and funding of clinical development.
- Whether inhaled ELX-02 CF development receives CFF or other funding, given the discontinued subcutaneous program and missed Phase 2 endpoints.
- Nasdaq listing status, potential equity issuance and dilution, and the availability of any remaining Hercules financing.